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Aims The purpose of the present analysis was to identify predictors of procedural success of percutaneous transcatheter
aortic valve implantation (TAVI).
Methods
and results
We prospectively assessed in-hospital outcome of patients undergoing TAVI at two institutions. We analysed clinical,
morphological, and procedural parameters using univariate and multivariate regression models. Between 2005 and
2008, a total of 168 consecutive patients with symptomatic aortic valve stenosis underwent TAVI using the self-
expanding CoreValve Revalving prosthesis. Patients (93%) were highly symptomatic with a New York Heart Associ-
ation grade III/IV and a mean aortic valve area of 0.66+0.21 cm2. Acute and in-hospital procedural success rates
were 90.5 and 83.9%, respectively, with an in-hospital mortality, myocardial infarction, and stroke rate of 11.9, 1.8,
and 3.6%, respectively. Predictors of in-hospital procedural success were type of access (OR 0.33, 95% CI 0.13–
0.82, P ¼ 0.017), prior coronary intervention (OR 5.3, 95% CI 1.20–23.41, P ¼ 0.028) and pre-procedural Karnofsky
index using univariate regression. Pre-procedural Karnofsky index emerged as the only independent predictor (OR
1.04, 95% CI 1.00–1.08, P ¼ 0.032) in the multivariate analysis.
Conclusion Pre-procedural functional performance status predicts the in-hospital outcome after TAVI. Patients with a good func-
tional status are likely to benefit more from TAVI than previously reported high-risk patients.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Percutaneous aortic valve implantation † Aortic stenosis † Predictors
Introduction
Transcatheter aortic valve implantation (TAVI) has rapidly been
implemented as a new and less-invasive treatment option for
patients with severe symptomatic aortic valve stenosis at high sur-
gical risk. Since the first-in-man experience in 2002,1 the technol-
ogy has significantly improved with the development of smaller
profile delivery catheters and better prostheses with availability
of various sizes. Presently, two different techniques are commer-
cially available: the balloon-expandable Edwards SAPIEN prosthesis
(Edwards Lifesciences, Irvine, CA, USA) and the self-expanding
CoreValve Revalving system (Medtronic, Minneapolis, MN, USA;
Figures 1 and 2). Both devices have been described in detail in pre-
vious publications,1 –10 and more than 4000 patients have now
been treated worldwide with one of these techniques.
Data on procedural performance, safety, and efficacy are yet still
limited. Using the latest devices in experienced centres, procedural
success rates of up to 96% with a 30 day mortality rate of 7–12%
have been reported,8– 10 in patients deemed at high surgical risk
with numerous co-morbidities. However, predictors of procedural
success are not well established. As with all new techniques, there
is an operator learning curve, which influences early outcome. This
holds true particularly for TAVI, a demanding procedure with
several new features compared with standard interventional
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techniques, such as dealing with a large arterial access, manoeuvr-
ing a large-profile device retrogradely through the aorta as well as
the implantation steps of the prosthesis itself within the native, dis-
eased aortic valve. Even if the operator is familiar with the tech-
nique, procedural success still varies over a wide range between
70 and 96%,7– 10 indicating additional obstacles. Therefore, we
aimed at identifying predictors of in-hospital procedural success,
defined as successful device implantation without in-hospital
major adverse cardiac and cerebral adverse events (MACCE).
Methods
Patient population
Between February 2005 and June 2008, 168 consecutive patients
underwent TAVI using the CoreValve Revalving device (Figures 1 and
2) at two institutions with TAVI expertise, HELIOS Klinikum Siegburg,
Siegburg, Germany (138 patients), and Bern University Hospital, Bern,
Switzerland (30 patients). As the CoreValve Revalving prosthesis
received European market approval in 2007, the present patient popu-
lation encompasses patients included during the early safety and effi-
cacy studies as well as post-approval registry patients.
Patient screening and eligibility
All patients underwent a pre-interventional screening process to
determine eligibility. Coronary anatomy and haemodynamic status
were evaluated by coronary angiography and complete left and right
heart catheterization. The valvular anatomy was assessed using trans-
thoracic and transoesophageal echocardiography, contrast angiography
of the aortic root and multi-slice computer tomography (MSCT) of the
thoracic aorta as the key screening methods. Annulus dimensions were
obtained from three-dimensional multi-planar MSCT reformation due
only to its accuracy and robustness in visualizing the region of interest
with minimized artificial effects as opposed to echocardiography. Vas-
cular access was assessed using MSCT of the abdominal aorta, and the
iliac and femoral vessels. The baseline surgical risk was estimated by
use of the logistic EuroSCORE. Eligibility of patients included into
the safety and efficacy studies was dependent on the study-specific
inclusion and exclusion criteria described elsewhere.5,7,9 Patient eligi-
bility of the post-approval series was similar to the safety and efficacy
studies. Patients were considered suitable if they (i) fulfilled the ana-
tomical requirements (Figure 3) and (ii) were considered at high surgi-
cal risk as confirmed by a senior cardiologist and cardiac surgeon.
Device and procedure
Design characteristics of the self-expanding CoreValve Revalving pros-
thesis (Figure 1) as well as the procedural characteristics have been
described previously.4,5,7,9 Briefly, the CoreValve prosthesis consists
of a tri-leaflet bioprosthetic porcine pericardial tissue valve, which is
sutured into a self-expanding nitinol frame. The sizes of three sub-
sequently developed delivery systems have been gradually reduced
from 25 French (Generation 1) and 21 French (Generation 2) to 18
French (Generation 3) over time which facilitated vascular access
and deployment of the device. For the current Generation 3 device,
two different sizes are available accommodating annulus dimensions
from 19 to 27 mm.
While the implants of Generation 1 and majority of Generation 2
required surgical access to the iliac arteries requiring general anaesthe-
sia, the Generation 3 device can be implanted percutaneously under
sedoanalgesia. Vascular access can be obtained with standard percuta-
neous access techniques and percutaneous closure using a pre-loaded
suture device (e.g. Prostar XL suture device, Abbott Vascular, Abbott
Park, IL, USA).
After mandatory pre-dilation of the native aortic valve, the prosthe-
sis is advanced retrogradely and deployed within the aortic annulus.
Figure 1 CoreValve prosthesis.
Figure 2 CoreValve prosthesis after successful implantation.
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Statistical analysis
Potential predictors for in-hospital procedural success were divided
into clinical, quantitative morphological, and procedural variables. Clini-
cal variables included the parameters presence of congestive heart
failure, diabetes, renal insufficiency (creatinine .1.2 mg/dL), smoking,
arterial hypertension, pulmonary hypertension (mean pulmonary
artery pressure at rest .25 mmHg), coronary artery disease, prior
stroke, prior myocardial infarction, prior percutaneous coronary inter-
vention (PCI), prior coronary artery bypass grafting, pre-procedural
New York Heart Association (NYHA) class, pre-procedural Karnofsky
index (see Appendix),11 and logistic EuroSCORE. Quantitative morpho-
logical variables included pre-procedural aortic regurgitation, pre-
procedural peak aortic valve gradient, pre-procedural mean aortic
valve gradient, pre-procedural mean aortic valve area, left ventricular
ejection fraction, and annulus diameter by MSCT. Procedural variables
included use of a large prosthesis, pre-dilation balloon diameter, post-
dilation performed, post-dilation balloon diameter, access (femoral,
iliac, subclavian artery). Details on parameter characteristics are
listed in Appendix 1.
Categorical variables are presented as frequencies and were com-
pared by chi-square test or Fisher’s exact test. Continuous variables
are presented as mean+ standard deviation and were compared by
unpaired Student’s t-test. Univariate logistic regression was performed
on all variables to identify determinants for in-hospital procedural
success, in-hospital major adverse cardiac and cerebrovascular
events (MACCE), and death. A P-value of ,0.20 at the univariate
stage was the method of selection of potential predictive factors in
the comparison of incidence rates. Next, relationships of event inci-
dence to selected covariates were investigated with multivariate logis-
tic regression models. All statistical tests were bilateral and a P-value of
,0.05 was considered significant in the final modelling.
Statistical analyses were conducted by Medpass International, Paris,
France. The authors had full access to and take full responsibility for
the integrity of the data. All authors have read and agreed to the
manuscript as written. All patients provided written informed
consent prior to the procedure. The study as well as informed
consent procedures were approved by the local ethics committees
at each institution.
Outcome definitions
In-hospital procedural success was defined as device success with the
absence of MACCE during the in-hospital period. Acute procedural
success was defined as device success with the absence of peri-
procedural MACCE during the first 24 h after device implantation.
Device success was defined as stable device placement and adequate
function without severe aortic regurgitation during the first attempt
as assessed by angiography and echocardiography. MACCE consisted
of death from any cause, myocardial infarction (creatine kinase-
myocardial band more than two times the upper limit of normal;
measured routinely post procedure and on Day 1 as well as in case
of clinical need), and stroke (as assessed by routine neurological
assessment before and after procedure and before hospital discharge).
Clinical adverse events were adjudicated by an independent clinical
events committee.
Results
Patient population
Patient baseline and procedural characteristics are listed in
Table 1. A total of 168 patients out of 380 patients with aortic
valve stenosis and high surgical risk entering the MSCT screening
process underwent TAVI at two institutions and were included in
this analysis. In 14.2% of screened patients, eligibility criteria were
fulfilled and TAVI procedure was intended, but not yet per-
formed, during the study period. Patients were not eligible for
the TAVI procedure due to inadequate annulus sizes (27.2%,
with annulus range inclusion criterion of ‘20–23 mm’, early one
device size generation; 4.2%, with annulus range inclusion
criterion of ‘20–27 mm’, current two device size generations),
peripheral artery disease (19.8%), excessive valve calcifications
(2.4%), and aneurysms of the ascending aorta (1.4%). Surgical
valve replacement was performed in 12.3% of patients without
TAVI exclusion criteria based on the interdisciplinary clinical
judgment, and in 21.2% of patients, the TAVI procedure was
not performed due to lack of clinical indication (including
reduced life expectancy for other reasons, bleeding risk) or
patient preferences.
The mean patient age of patients undergoing TAVI was 81.9+
6.7 years. Pre-procedural functional status as assessed by the Kar-
nofsky index (functional performance scale, see Appendix) was
10–40 (severely reduced) in 48% of these patients, mean 44.8,
median 50, range 20–80. Patients were severely symptomatic
(NYHA class III/IV: 93% of patients) with a mean aortic valve
area of 0.66+0.21 cm2, mean pressure gradient was 43.2+
16.9 mmHg. None or mild pre-procedural aortic regurgitation
was present in 80.8% of patients.
Acute and in-hospital outcome
The acute and in-hospital procedural success rates in the study
population were 90.5 and 83.9%, respectively (Table 2). The
in-hospital MACCE rate was 16.7%, with an in-hospital mortality,
Figure 3 Anatomical requirements for CoreValve implantation.
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myocardial infarction, and stroke rate of 11.9, 1.8, and 3.6%,
respectively. In-hospital mortality was primarily related to pro-
gressive heart failure, dominantly right heart failure, as well as
pneumonia, sepsis, and mesenterial infarction. Acute device
success was observed in 93.5%.
Univariate and multivariate analyses
Results of the univariate and multivariate analyses are presented in
Tables 3–8. Univariate analysis identified two potential clinical pre-
dictors [pre-procedural Karnofsky index, odds ratio (OR) 1.04,
95% confidence interval (CI) 1.01–1.08, P ¼ 0.01; prior PCI, OR
5.3, 95% CI 1.20–23.41, P ¼ 0.028; Table 3] and one procedural
predictor (access site, OR 0.33, 95% CI 0.13–0.82, P ¼ 0.017;
Table 5) for in-hospital procedural success. In the multivariate
analysis, pre-procedural Karnofsky index emerged as the only inde-
pendent predictor for in-hospital procedural success (OR 1.04,
95% CI 1.00–1.08, P ¼ 0.032; Table 6). There was a trend for
the variable access site (OR 0.48, 95% CI 0.18–1.27, P ¼ 0.139),
but this did not reach significance in the multivariate analysis.
The multivariate predictor analysis for any major adverse event
including death, stroke, and myocardial infarction—as part of
in-hospital success—as well as mortality alone revealed a predic-
tive impact of the pre-procedural Karnofsky index (any MACCE:
OR 0.98, 95% CI 0.93–1.00, P ¼ 0.025; death alone: OR 0.97,
95% CI 0.93–1.00, P ¼ 0.051; Tables 7 and 8).
Discussion
Transcatheter aortic valve implantation success is influenced by
numerous factors, including operator experience and patient selec-
tion. Particularly, the operator learning curve affects the outcome
in the first cases of each centre. However, even beyond this learn-
ing period, procedural outcome varies, with procedural failure
rates of approximately 5–25%.7 –9 Therefore, it is of importance
to identify factors which predict the outcome of TAVI in clinical
practice.
We have analysed various clinical, quantitative morphological,
and procedural parameters potentially affecting procedural
outcome based on the combined TAVI experience of two insti-
tutions. In-hospital procedural success was chosen as the principal
outcome parameter, as it reflects a combination of feasibility,
safety, and efficacy in a clinically relevant way, indicating the
amount of patients discharged after TAVI without major compli-
cations including death, stroke, or myocardial infarction.
The in-hospital procedural success rate amounted to 83.9% in
the present report, with an acute device and procedural success
rate of 93.5 and 90.5%, respectively, which is in line with previous
publications.8– 10
The only independent predictive parameter of in-hospital pro-
cedural success was the pre-procedural functional performance
status of the patient, as expressed in our study by the Karnofsky
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Table 1 Patient baseline and procedural
characteristics
Number of patients 168
Age, years 81.9+6.7
Male gender 73 (43.5%)
Clinical characteristics
Hypertension 127 (75.6%)
Renal insufficiency 44 (26.2%)
Coronary heart disease 99 (58.9%)
Pulmonary hypertension 36 (21.4%)
Congestive heart failure 55 (32.7%)
Smoker 22 (13.1%)
Diabetes 47 (28.0%)
Prior stroke 15 (8.9%)
Prior myocardial infarction 41 (24.4%)
Prior PCI 44 (26.2%)
Prior CABG 49 (29.2%)
Pre-procedural NYHA grade
III 112 (67.1%)
IV 43 (25.7%)
Pre-procedural Karnofsky index
10–40 81 (48.2%)
50–70 85 (50.6%)
80–100 2 (1.2%)
Logistic EuroSCORE 23.8+15.4%
STS score: mortality 9.0+6.0%
Quantitative morphological characeristics
Pre-procedural aortic valve area 0.66+0.21 cm2
Pre-procedural peak valve gradient 69.9+24.0 mmHg
Pre-procedural mean valve gradient 43.2+16.9 mmHg
Pre-procedural aortic regurgitation grade
None/mild 135 (80.8%)
Moderate 29 (17.4%)
Severe 3 (1.8%)
Annulus diameter by CT-Scan 23.6+1.5 mm
Ejection fraction 51.3+16.3%
Procedural characteristics
Access
Femoral 155 (92.3%)
Iliac 10 (6.0%)
Subclavian 3 (1.8%)
Pre-dilation balloon diameter 22.5+1.5 mm
Post-dilation performed 92 (55.4%)
Post-dilation balloon diameter 25.4+2.5 mm
Use of large prosthesis 53 (31.9%)
Length of Hospital Stay, median 9 days
Table 2 Procedural success and in-hospital outcome
Procedural success, acute 152 (90.5%)
Device success, acute 157 (93.5%)
Death, in-hospital 20 (11.9%)
Stroke, in-hospital 6 (3.6%)
Myocardial infarction, in-hospital 3 (1.8%)
Procedural success, in-hospital 141 (83.9%)
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index—though the effect was mild just reaching significance. This
observation is primarily driven by a significant influence of the pre-
procedural Karnofsky index on the incidence of MACCE, namely
the rate of death. The univariate analysis identified the access
site as another potential predictor for in-hospital procedural
success without significance in the multivariate analysis. In other
words, the in-hospital outcome might have been partially affected
by the selection of the access site, favouring the femoral over the
iliac and subclavian access. However, the number of patients with
non-femoral access is comparatively low, limiting the ability to
draw meaningful conclusions from this finding.
This observation of a predictive effect of the Karnofsky index is
of importance for future TAVI studies, as it might shift the clinical
relevance of scoring systems from the historically used, more
co-morbidity-based EuroScore or Society of Thoracic Surgeons
(STS) score towards functional assessment scales (frailty indices).
Accordingly, it is not the sum of various individual co-morbidities
that predicts the procedural risk, but rather their consequences
on the functional and clinical status of the patient. This finding is
not surprising—a frail patient usually has a slower and more com-
plicated recovery than a physically healthy one—but its impact on
procedural success and in-hospital mortality has not previously
been validated in the field of TAVI.
In this study, we have chosen the Karnofsky index as functional
performance scale, which originates from the field of oncology
owing to its simplicity. However, there are multiple functional
Table 3 Univariate predictor analysis for in-hospital procedural success of transcatheter aortic valve implantation—
clinical predictors
Table 4 Univariate predictor analysis for in-hospital procedural success of transcatheter aortic valve implantation—
morphological predictors
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Table 5 Univariate predictor analysis for in-hospital procedural success of transcatheter aortic valve implantation—
procedural predictors
Table 6 Multivariate predictor analysis for in-hospital procedural success of transcatheter aortic valve implantation
Table 7 Multivariate predictor analysis for any in-hospital major adverse cardiac and cerebral adverse events after
transcatheter aortic valve implantation
Table 8 Multivariate predictor analysis for in-hospital death after transcatheter aortic valve implantation
Transcatheter aortic valve implantation 989
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performance scales available, which might be valuable as well.
Additional studies on larger patient populations focusing on this
important aspect are certainly needed to confirm this finding.
The result of the univariate analysis with a predictive value of the
type of access site, favouring femoral access over iliac and subcla-
vian access, helps to understand the improvement of published
outcome rates over the past few years. The main benefit of the
profile size reduction of the CoreValve prosthesis from Gener-
ation 1 (25 French) over Generation 2 (21 French) to the Gener-
ation 3 (18 French) was to allow the shift of access site from a
more central location—iliac—to a more peripheral—femoral—
position. This resulted in the ability to perform the procedure in
a truly percutaneous fashion, without the risk of complications
associated with the access surgery—which was required to open
as well as close the iliac artery—or the accompanying general
anaesthesia. However, these technical changes did not affect the
predictive importance of the patient’s functional condition as
shown above.
If confirmed in larger studies, the finding of a correlation of pre-
procedural frailty and post-procedural outcome might be impor-
tant for future studies in the field of TAVI as it may open the
door towards inclusion of lower-risk patients as presently enrolled.
Up to now, it has been uncertain whether a complication after
TAVI was procedure-related or mainly related to the patient’s pre-
procedural functional status and co-morbidities. The present data
support the notion that the healthier the patient is before the pro-
cedure the better is his outcome after TAVI. Accordingly, compli-
cation and success rates of TAVI as currently reported in patients
at high surgical risk cannot be translated to lower risk patients with
a good functional performance status. TAVI in patients at low sur-
gical risk might yield better feasibility and safety results than the
presently reported ones.
Limitations
The present analysis is based on consecutive cohorts of two
centres with considerable TAVI experience. Notwithstanding, the
overall number of patients is small, which might affect the validity
of the predictor analysis due to lack of sufficient power particularly
with respect to the detection of confounding factors. Larger
studies are needed to confirm these findings. To expand the
overall patient population, the entire TAVI cohort has been
included in both centres, also comprising the patients of the learn-
ing phase as well as the patients included during the evaluation of
first- and second-generation devices at HELIOS Heart Center
Siegburg. Exclusion of these patients would have limited the
event numbers and hence the ability to perform the predictor
analysis. Only the self-expanding CoreValve Revalving prosthesis
has been studied in this analysis. Separate studies are needed to
confirm these findings for patients treated with a balloon-
expandable aortic valve prosthesis. The Karnofsky index has
been chosen for assessment of the functional patient status
which has not been validated in patients undergoing TAVI. Other
frailty scores might be more suitable to assess the patient perform-
ance. However, none of the presently available scoring systems are
validated in this new field of interventional cardiology. The STS
score was calculated retrospectively in the study patient popu-
lation and added for descriptive purposes in the patient character-
istic table, but was not considered as a parameter in the present
analysis. Since the focus of this analysis was prediction of
MACCE with relevant clinical sequelae, namely death, stroke,
and myocardial infarction, we did not include complications such
as need for pacemaker or bleeding in our success definition.
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Appendix 1: parameter characteristics
Parameter Type of data Data source or method of assessment
Presence of
Congestive heart failure Dichotomous nominal (yes/no) Medical history and pre-procedural on-site exam
Diabetes Dichotomous nominal (yes/no) Medical history and pre-procedural on-site exam
Renal insufficiency Dichotomous nominal (yes/no) Medical history and pre-procedural on-site exam
Smoker Dichotomous nominal (yes/no) Medical history and pre-procedural on-site exam
Hypertension Dichotomous nominal (yes/no) Medical history and pre-procedural on-site exam
Pulmonary hypertension Dichotomous nominal (yes/no) Medical history and pre-procedural on-site exam
Coronary artery disease Dichotomous nominal (yes/no) Medical history and pre-procedural on-site exam
Prior stroke Dichotomous nominal (yes/no) Medical history
Prior myocardial infarction Dichotomous nominal (yes/no) Medical history
Prior PCI Dichotomous nominal (yes/no) Medical history
Prior coronary artery bypass grafting Dichotomous nominal (yes/no) Medical history
Continued
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Continued
Parameter Type of data Data source or method of assessment
Pre-procedural NYHA Ordinal (I, II, III, IV) Pre-procedural on-site examination
Pre-procedural Karnofsky index Ordinal (0,10, . . . ,90, 100) Pre-procedural on-site examination
Logistic EuroScore Continuous Pre-procedural on-site calculation
Pre-procedural aortic regurgitation Ordinal (0, 1þ, 2þ, 3þ, 4þ) Pre-procedural echo screening
Pre-procedural peak aortic valve gradient Continuous Pre-procedural echo screening
Pre-procedural mean aortic valve gradient Continuous Pre-procedural echo screening
Left ventricular ejection fraction Continuous Pre-procedural echo screening
Annulus diameter Continuous Pre-procedural MSCT screening
Use of a large prosthesis Dichotomous nominal (yes/no) Procedural data
Pre-dilation balloon diameter Continuous Procedural data
Post-dilation performed Dichotomous nominal (yes/no) Procedural data
Post-dilation balloon diameter Continuous Procedural data
Access Nominal (femoral, iliac, subclavian) Procedural data
In-hospital procedural success Dichotomous nominal (yes/no) Post-procedural clinical follow-up
In-hospital MACCE Dichotomous nominal (yes/no) Post-procedural clinical follow-up
In-hospital death Dichotomous nominal (yes/no) Post-procedural clinical follow-up
PCI, percutaneous coronary intervention; NYHA, New York Heart Association; MACCE, major adverse cardiac and cerebral events.
Appendix 2: Karnofsky performance status scale: definitions
100 Normal no complaints; no evidence of disease. Able to carry on normal activity and to work; no special care needed.
90 Able to carry on normal activity; minor signs or symptoms of disease.
80 Normal activity with effort; some signs or symptoms of disease.
70 Cares for self; unable to carry on normal activity or to do active work. Unable to work; able to live at home and care for most personal
needs; varying amount of assistance needed.60 Requires occasional assistance, but is able to care for most of his personal needs.
50 Requires considerable assistance and frequent medical care.
40 Disabled; requires special care and assistance. Unable to care for self; requires equivalent of institutional or hospital
care; disease may be progressing rapidly.30 Severely disabled; hospital admission is indicated although death not imminent.
20 Very sick; hospital admission necessary; active supportive treatment necessary.
10 Moribund; fatal processes progressing rapidly.
0 Dead
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